Skip to main content
Journal ArticleOPEN ACCESS

9. Evaluation of Synergy Testing Methods for Clinical Labs to Determine Susceptibility of Extensively Drug-resistant Gram-negatives to Ceftazidime/ Avibactam and Aztreonam Combination Therapy

  • Khan A
  • Erickson S
  • Pettaway C
  • et al.
Open Forum Infectious Diseases (2020) 7(Supplement_1) S5-S6
DOI: 10.1093/ofid/ofaa417.008
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Oral Abstracts • OFID 2020:7 (Suppl 1) • S5 Conclusion. RZV demonstrated high VE against HZ until the end of the observation period for this Y2 interim analysis. The HI and CMI responses remained stable and high until the end of observation (i.e. 7.1 years after initial vaccination).

Cite

CITATION STYLE

APA

Khan, A., Erickson, S. G., Pettaway, C. H., Arias, C. A., Miller, W. R., & Bhatti, M. M. (2020). 9. Evaluation of Synergy Testing Methods for Clinical Labs to Determine Susceptibility of Extensively Drug-resistant Gram-negatives to Ceftazidime/ Avibactam and Aztreonam Combination Therapy. Open Forum Infectious Diseases, 7(Supplement_1), S5–S6. https://doi.org/10.1093/ofid/ofaa417.008

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free